After the first description of BBSOAS, patients with NR2F1 mutations from distinct cohorts could finally be grouped into a single clinical category under the name of a novel syndrome. This evidence concerns the gene NR2F1 and Bosch-Boonstra-Schaaf optic atrophy syndrome.